Gland Pharma Limited — Q4 FY25 earnings call

Call held 20 May 2025

Management summary

Gland Pharma reported a quarter of mixed results, characterized by a flat full-year revenue performance but significant strategic progress in high-growth areas like GLP-1s and Biologics. While the base business remains highly profitable with 38% EBITDA margins, the Cenexi acquisition continues to be a drag on consolidated performance, though management expects an EBITDA-positive turnaround by Q3 FY26. The company is aggressively expanding its cartridge capacity to 140 million units to capture the burgeoning GLP-1 market.

Highlights

  • Consolidated Revenue for Q4 FY25 stood at ₹1,424.9 crores, showing sequential improvement over Q3.

  • Consolidated EBITDA margin expanded to 24%, a 100bps increase year-over-year.

  • Base business (excluding Cenexi) reported a healthy EBITDA margin of 38% for the quarter.

  • Net Profit (PAT) for Q4 increased by 3% YoY to ₹186.5 crores.

  • Successful entry into the GLP-1 segment with the launch of liraglutide and two secured contracts.

  • US market top 10 molecules grew by 26% in volume, despite pricing adjustments due to lower material costs.

  • Cenexi gross margin improved to 79% from 77% in the prior quarter, despite operational challenges at the Fontenay facility.

  • Net cash position remains strong at ₹2,287 crores as of March 31, 2025.

Concerns

  • US Reciprocal Tariffs

Key financials

  1. Revenue ₹1,424.9 Cr +10%QoQ
  2. EBITDA Margin 24%
  3. PAT ₹186.5 Cr +3%YoY
  4. R&D Spend ₹50.3 Cr +15%YoY
  5. Net Cash ₹2,287 Cr

What they filed

Q1 FY27: revenue up 23.9%, net profit up 35.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue1,063 1,011 1,030 1,039 1,074 +1%1,178 +17%1,262 +23%1,287 +24%
EBITDA364 391 394 359 375 +3%422 +8%508 +29%474 +32%
Net profit282 295 290 269 302 +7%308 +4%420 +45%364 +35%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Base Business (Ex-Cenexi)
    ₹1,033.2 Cr Revenue38% EBITDA Margin-12% YoY Growth
  • Cenexi
    43 million euro Revenue79% Gross Margin

Guidance & targets

Revenue

  • Consolidated Revenue Growth Revenue · FY26 · High confidence 15%
    And also, we are looking at as a business, we are looking at mid-teens as growth for the coming year.

    — Srinivas Sadu, Executive Chairman

  • US Revenue Growth Revenue · FY26 · High confidence 18%
    So, US, the estimate is next year, 18%, 12% of the products and 6% from the CMO projects to the US.

    — Srinivas Sadu, Executive Chairman

  • Biologics Revenue Revenue · FY26 · High confidence ₹100 crores
    Yes, for FY2'6 it will be about Rs 100 crores, I would say. Then it will gradually increase.

    — Srinivas Sadu, Executive Chairman

  • Cenexi Revenue Target Revenue · next 3 years · Medium confidence €300 million
    this will take our revenue to not 200, but 300 million in 3 years' time.

    — Ravi Mitra, CFO

Capacity

  • Cartridge Capacity Capacity · by CY 2026 · High confidence 140 million units

    From 40 million units today

    we are scaling our cartridge capacity from the current 40 million units to an additional 100 million by CY 2026.

    — Srinivas Sadu, Executive Chairman

Market context

  • Cenexi EBITDA Breakeven Profitability · Q3 FY26 · Medium confidence Positive
    We remain firmly focused on achieving our medium-term objective of delivering positive EBITDA by Q3 FY26.

    — Alain Kirchmeyer, CEO Cenexi

Risks & concerns

  • US Reciprocal Tariffs

    high

    Management notes a layer of uncertainty for Indian pharma companies due to potential US administration tariff announcements.

    Both acknowledged

  • Cenexi Operational Disruptions

    medium

    Ongoing remediation at Fontenay and equipment breakdowns impacted Q4 performance and shipments.

    Management acknowledged

  • ROW Tender Misses

    medium

    Delays in Saudi NUPCO contract due to tech transfer for local manufacturing of Enoxaparin.

    Management explained

Areas of evasion (2)

  • Specific order book details for Cenexi (asked for time to come back).
  • Exact number of first-to-file exclusivity ANDAs (deferred to provide later).

Q&A highlights

2 direct
Cenexi Capital Allocation and Business Viability Partial
Is this a business even worth pursuing based on whatever obviously benefits of hindsight and whatever your understanding is currently? Is it a business worth pursuing?

Analysts are openly questioning the strategic value of the Cenexi acquisition given the high cost and slow turnaround.

Asked by Dheeresh Pathak, WhiteOak

US Revenue Run-rate and Tariff Impact Direct
On the tariff side, it's too early to comment, but what we hear is for generics, it will not impact that much. And for us also, what we see is probably most of it will be passed on if there are any tariffs which are levied on Indian imports.

Clarifies management's stance on potential US trade policy risks and their ability to maintain margins via pass-through.

Asked by Neha Manpuria, Bank of America

GLP-1 Capacity Booking and Pricing Direct
That will be most of it will be consumed. So that's the reason why we have invested in the second line... the second line will be up and running by the end of this year.

Confirms strong demand for GLP-1 fill-finish services, justifying the aggressive capacity expansion.

Asked by Alankar Garude, Kotak Institutional Equities

2 min read 5 chapters

Detailed narrative

GLP-1 Segment Becomes a Strategic Pillar

Gland Pharma has successfully entered the GLP-1 market with the launch of liraglutide and secured two major contracts. To meet anticipated demand, the company is aggressively scaling its cartridge capacity from 40 million to 140 million units by CY 2026. Management expects this segment to be a significant volume driver, with fill-finish pricing estimated between $1 to $2 per unit.

Cenexi Turnaround and High-Value Shift

The Cenexi subsidiary remains a work in progress, with management shifting focus from low-value, high-volume business (previously 70% of operations) to high-value products like pre-filled syringes and lyophilized vials. Despite remediation challenges at the Fontenay site, gross margins improved to 79%. The company targets EBITDA breakeven for Cenexi by Q3 FY26 and €300 million in revenue within three years.

US Market Resilience Amid Pricing Pressure

The US business saw a 26% volume growth in its top 10 molecules during Q4. While revenue growth was tempered by lower transfer prices (driven by reduced material costs), margins remained intact. Management is targeting 18% growth in the US for FY26, supported by 31 new product launches in FY25 and a robust pipeline of RTU infusion bags and complex injectables.

Biologics CDMO Entry Gains Momentum

Gland is building a robust CDMO setup for biologics, with a key collaboration with Dr. Reddy's Laboratories expected to contribute revenue starting in FY26. The company is expanding its bioreactor capacity by 15,000 liters and expects the biologics segment to generate approximately ₹100 crores in revenue in the next fiscal year, marking a significant step into the biosimilars market.

ROW and Emerging Markets Expansion

Despite a 14% decrease in ROW revenue in Q4 due to tender misses and tech transfers in Saudi Arabia, Gland maintains a long-term vision to double this business over the next 3-5 years. The company has over 500 registrations pending in high-growth emerging markets and is leveraging its approved US/India portfolio to deepen its global reach.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls